Navigation Links
Baxa Corporation Signs Exclusive Distribution Agreement With Leading Pharmaceutical Corporation in People's Republic of China
Date:10/19/2009

ENGLEWOOD, Colo., Oct. 19 /PRNewswire/ -- Baxa Corporation, a US-based medical device company in Englewood, Colorado, has signed an exclusive four-year distribution agreement with SINOPHARM, a China National Pharmaceutical Foreign Trade Corporation, to promote sales of its products in China. While the agreement covers all Baxa products, the ExactaMix(TM) 2400 Automated Compounder and the Repeater(TM) Pharmacy Pump have been recognized as ones that will increase efficiency for the hospitals targeted by Baxa and SINOPHARM in the People's Republic of China (PRC). Due to their existing practice of manual preparation, the companies expect that more than 250 hospitals could benefit from the Baxa pharmacy automation equipment.

The partners anticipate that Baxa Corporation's expertise in automation could greatly improve the existing processes in Chinese hospitals - making their pharmacy operations more accurate, safe and efficient. "Baxa products are used all across the world every day by thousands of pharmacies. By entering the Chinese market, patients there will access the same outstanding quality that Baxa products have provided for 35 years in other parts of the world," states Phil Walsh, Baxa Director of International Sales.

"In China, the curtain has just been raised on the automation and digitization of the hospital pharmacy. Baxa products serve as an integral part for pharmacy automation," states Li Hai Bo, Medical Equipment Manager, SINOPHARM. "Parenteral nutrition is widely used in China," he continues, "however SINOPHARM believes that the current practice of manual preparation is inadequate and may not meet the varied needs of individual patients."

A key component of this partnership is the recent announcement of the China State Council to allocate 850 billion Yuan ($123 billion USD) to reform its medical and healthcare system. Technological advancement was cited as being vital to the plan's success in improving the quality of medical services to the country's 1.3 billion people.

Baxa Corporation was founded in 1975 by Brian Baldwin and Ronald Baxa. Through more than three decades of rapid growth and change in the healthcare industry, Baxa Corporation has become a leading global supplier of solutions for handling, measuring and administering fluid medications. In addition to its global headquarters in Englewood, CO, Baxa has subsidiaries and sales offices in Florida, Canada and the United Kingdom; direct representation within Europe and distribution partners worldwide.

About Baxa Corporation

Baxa, a customer-focused medical device company, provides innovative, solution-based technologies for medication handling and delivery. Its systems and devices promote the safe and efficient preparation, handling, packaging, and administration of medications. Key products include the PadLock® Set Saver, Rapid-Fill(TM) Automated Syringe Fillers, ExactaMed® Oral Dispensers, MicroFuse® Syringe Infusers, Repeater(TM) Pharmacy Pumps, the DoseEdge(TM) Dose Management System and ExactaMix(TM) Multi-Source Automated Compounders; used worldwide in hospitals and healthcare facilities. Its subsidiary FHT, Inc. produces the IntelliFill i.v. ® automation. Further information is available at www.baxa.com.

About SinoPHARM

Established in 1981, China National Pharmaceutical Foreign Trade Corporation (SINOPHARM Foreign Trade) is a wholly owned subsidiary of China National Pharmaceutical Group Corporation (SINOPHARM Group). SINOPHARM's core businesses are investment, import and export, and domestic distribution in pharmaceutical and relevant sections, including pharmaceutical R&D, consultation, bonded warehousing and other value-added services such as overseas pharmaceutical projects and domestic wholesale of pharmaceuticals, medical instruments and equipment. SINOPHARM keeps the country's medicine reserve and plays an important role in disaster and emergency relief and disease and plague prevention. For more information, visit http://www.sino-pharm.com.

    Contact:
    Marian Robinson, Vice President, Marketing
    Baxa Corporation:  800.567.2292 ext. 2157 or 303.617.2157
    Email:  marian.robinson@baxa.com

    Maggie Chamberlin Holben, APR
    Absolutely Public Relations: 303.984.9801 or 303.669.3558
    Email: maggie@absolutelypr.com

    Li Hai Bo, Medical Equipment Manager, Health Care Division
    SINOPHARM: +8610 82074502
    lihaibo@sinopharm.com

SOURCE Baxa Corporation


'/>"/>
SOURCE Baxa Corporation
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. Genaera Corporation Presents Interim Phase 1 Data for Obesity Compound Trodusquemine (MSI-1436) at IBC Conference
2. CEL-SCI Corporation Releases Letter to Shareholders
3. Alfacell Corporation to Present at UBS Global Life Sciences Conference
4. Baxa Corporation Extends Global Reach With New Distribution Agreements in Colombia and the Dominican Republic
5. Genaera Corporation Presents Preclinical Trodusquemine (MSI-1436) Data at the North American Association for the Study of Obesity Annual Meeting
6. Genaera Corporation Presents Phase 1 Data for Trodusquemine (MSI-1436) at the North American Association for the Study of Obesity Annual Meeting
7. The Quigley Corporation Reports Third Quarter Results, Increases Investment in Pharmaceutical R&D for Diabetic Neuropathy
8. Genaera Corporation Provides Highlights of Positive Phase 1 Trodusquemine (MSI-1436) Data from the North American Association for the Study of Obesity Annual Meeting
9. Crystal Research Associates, LLC Issues Executive Informational Overview(R) (EIO(R)) on CEL-SCI Corporation
10. Immunosyn Corporation Releases SF-1019 Study Results
11. AmpliMed Corporation Announces Promising 1-year Survival Data from Phase I/II Study of Amplimexon(R) in Metastatic Malignant Melanoma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/8/2016)... , Dec. 8, 2016  Eli Lilly and ... results of its phase 3 EXPEDITION3 trial at the ... meeting. As previously disclosed, solanezumab did not meet the ... of solanezumab initiated in people with mild dementia due ... regulatory submissions for solanezumab for the treatment of mild ...
(Date:12/8/2016)... de dezembro de 2016  A Mederi Therapeutics Inc . anunciou aprovação ... não cirúrgico para a doença do refluxo gastroesofágico (DRGE). Foto -  ... ... Live Stretta procedure performed and broadcast during the Chinese ... Union Hospital , ...
(Date:12/8/2016)... Pa. , Dec. 8, 2016  Pennsylvania ... Secretary of Drug and Alcohol Programs Gary ... and insomnia medications, known as benzodiazepines, developed with ... "Benzodiazepines are medications that are frequently prescribed ... when they are used with opioid pain medications, ...
Breaking Medicine Technology:
(Date:12/9/2016)... ... December 09, 2016 , ... Sober College, ... with the grand opening of the Sober College Robert Pfeifer Memorial Learning Center ... December 2-3, and was attended by an overwhelming amount of alumni, family, colleagues ...
(Date:12/9/2016)... , ... December 09, 2016 , ... "I had a ... inventor from Winchester, Va. "I thought that if the nebulizer had a more child-friendly ... than fearing them." , He developed the patent-pending NEBY to avoid the need to ...
(Date:12/8/2016)... , ... December 08, 2016 , ... ... Franchising Company LLC, announced the first national #QuackGivesBack campaign which supported local ... “This was our first franchise-wide Quack Gives Back initiative, and we’re ...
(Date:12/8/2016)... ... December 08, 2016 , ... With the increasing demand for dental implants, the ... (WIYM) campaign to inform dentists and patients about the safety issues related to dental ... market in the U.S. is projected to reach $6.4 billion in 2018 with more ...
(Date:12/8/2016)... ... 2016 , ... Catalent Pharma Solutions, the leading global provider ... products, today announced that it had joined the Pharmaceutical Supply Chain Initiative (PSCI). ... unite pharmaceutical and healthcare companies that share a vision of better, social, environmental ...
Breaking Medicine News(10 mins):